VTGN Nasdaq

VistaGen Therapeutics, Inc.

VTGN | $4.83 1.05% 1.04% 190K

(0.0% 1d) (11.7% 1m) (12.7% 1y) (0.0% 2d) (0.0% 3d) (2.4% 7d) (-9.14% volume)
Earnings Calendar: 2024-02-06
Market Cap: $ 130,531,759
http://www.vistagen.com
Sec Filling | Patents | 9 employees

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of new generation medicines to treat diseases and disorders of the central nervous system. Its portfolio focuses on three clinical-stage product; neuropathic pain (NP), levodopa-induced dyskinesia (LID), social anxiety disorder (SAD) and suicidal ideation (SI). Its product include AV-101 product and PH10 neuroactive nasal spray.The company was founded by H. Ralph Snodgrass and Gordon Keller on May 26, 1998 and is headquartered in South San Francisco, CA.

nervous system social anxiety disorder

add to watch list Paper trade email alert is off

Press-releases

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Published: 2024-04-09 (Crawled : 14:30) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| -7.54% | O: 0.58% H: 3.65% C: 3.27%
conference association depression

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| -9.47% | O: -2.27% H: 0.0% C: 0.0%
positive treatment results study

Vistagen to Present at Stifel 2024 Virtual CNS Days
Published: 2024-03-11 (Crawled : 15:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 13.54% | O: -0.48% H: 2.74% C: -0.48%

Vistagen to Present at TD Cowen 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 14:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| -9.64% | O: 0.95% H: 0.0% C: -2.43%
conference health care

Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024
Published: 2024-02-06 (Crawled : 14:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 4.14% | O: -0.87% H: 6.59% C: 5.49%
conference report year update financial results

Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results
Published: 2023-11-09 (Crawled : 23:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 55.19% | O: 0.32% H: 2.23% C: -6.47%
update financial results

Vistagen to Present at Stifel 2023 Healthcare Conference
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 37.55% | O: -2.16% H: 0.88% C: -9.41%
conference

Vistagen to Present Positive Fasedienol Phase 3 Data and Positive PH80 Phase 2A Data at Upcoming Scientific Conferences
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 41.0% | O: -0.59% H: 3.86% C: 3.12%
ph80 positive

Vistagen To Report Second Quarter Financial Results and Host Corporate Update Conference Call on November 9, 2023
Published: 2023-11-06 (Crawled : 14:30) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 42.69% | O: 1.49% H: 3.03% C: -0.29%
conference report update financial results

Vistagen to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
VTGN | $4.83 1.05% 1.04% 190K

Health Technology

| 39.36% | O: 0.29% H: 3.49% C: -9.45%
biotech

See all